Insider Shareholders with Direct Ownership of Trevi Therapeutics, Inc. (TRVI)
This section provides a comprehensive overview of the insiders with direct ownership of Trevi Therapeutics, Inc. (TRVI). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Trevi Therapeutics, Inc. Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
New Enterprise Associates 16, L.P.
> 10% Shareholder |
4,483,430 | 0 | 10,421,428 $42.3 Million | 2 |
Apr 11, 2022
Added 20.16%
|
4,555 | 4,555 | 352,489 $1.43 Million | 2 |
Aug 27, 2024
Reduced 1.28%
|
|
Thomas Sciascia
Chief Scientific Officer |
107,355 | 101,369 | 220,315 $894,478 | 10 |
Aug 19, 2024
Reduced 6.97%
|
Jennifer L Good
President & CEO |
90,795 | 90,795 | 213,313 $866,050 | 14 |
Sep 09, 2024
Reduced 0.86%
|
Lisa Delfini
Chief Financial Officer |
61,875 | 18,593 | 53,279 $216,312 | 20 |
May 22, 2024
Reduced 7.55%
|
Farrell Simon
Chief Commercial Officer |
25,000 | 0 | 45,650 $185,338 | 2 |
Jun 20, 2023
Added 12.04%
|
15,000 | 0 | 19,935 $80,936 | 1 |
Dec 13, 2024
Added 42.94%
|